```html

Valve Disease (Heart Valve Disease) – A Complete Patient Guide

Overview

Heart valve disease refers to any condition that impairs the function of one or more of the four cardiac valves (aortic, mitral, pulmonary, and tricuspid). The valves act as one‑way doors that keep blood flowing in the correct direction. When a valve is damaged, it may **stenose** (narrow) or **regurgitate** (leak), forcing the heart to work harder and eventually leading to symptoms such as shortness of breath, fatigue, or chest discomfort.

Who it affects: Valve disease can occur at any age, but the most common forms—​aortic stenosis, mitral regurgitation, and mitral stenosis—​usually appear in adults over 60. Congenital (present at birth) valve defects affect 1–2 % of newborns, while acquired disease accounts for the majority of adult cases.

Prevalence (2023 data):

• Approximately 2.5 %** of adults in the United States have clinically significant valve disease (≈ 8 million people) – CDC.
• Aortic stenosis is the most common valve problem in people > 75 years, affecting about **3 %** of that age group (Mayo Clinic).
• Rheumatic heart disease, once a leading cause worldwide, now accounts for 1–2 %** of cases in high‑income countries but 30 % in low‑resource regions (WHO).

Symptoms

Symptoms vary depending on which valve is involved, the severity of the lesion, and the speed of disease progression. Early disease may be silent.

Common signs across most valve disorders

• Shortness of breath (dyspnea) – especially with exertion or when lying flat (orthopnea).
• Fatigue or reduced exercise tolerance – the heart cannot pump enough oxygen‑rich blood.
• Chest discomfort or pressure – may mimic angina, particularly with aortic stenosis.
• Palpitations – irregular heartbeats caused by atrial enlargement.
• Swelling (edema) – especially in the ankles, feet, or abdomen, reflecting fluid buildup.
• Light‑headedness or fainting (syncope) – a red‑flag for severe obstruction (e.g., aortic stenosis).

Valve‑specific symptom patterns

• Aortic Stenosis: crescendo‑decrescendo systolic ejection murmur, chest pain on exertion, fainting spells, heart murmur radiating to the neck.
• Aortic Regurgitation: bounding pulse, “water‑hammer” pulse, early diastolic murmur, wide pulse pressure, rapid fatigue.
• Mitral Stenosis: symptoms worsen after pregnancy or with atrial fibrillation; “opening snap” followed by diastolic rumble, pulmonary congestion.
• Mitral Regurgitation: holosystolic murmur at the apex, radiating to the axilla, early onset dyspnea, possible atrial fibrillation.
• Tricuspid Regurgitation: prominent jugular venous pulsations, hepatic congestion, peripheral edema.
• Pulmonic (Pulmonary) Stenosis (rare in adults): systolic murmur, cyanosis, right‑ventricular hypertrophy.

Causes and Risk Factors

Primary (non‑infectious) causes

• Degenerative calcification – age‑related calcium deposits on the aortic or mitral annulus (most common in the elderly).
• Congenital malformations – bicuspid aortic valve (present in ~1–2 % of the population) predisposes to early stenosis.
• Connective‑tissue disorders – Marfan, Ehlers‑Danlos, and Loeys‑Dietz syndromes increase risk of mitral prolapse and aortic root dilation.
• Radiation therapy to the chest (e.g., for Hodgkin lymphoma) can cause late valve fibrosis.

Secondary (acquired) causes

• Rheumatic fever – autoimmune reaction after Streptococcus pyogenes infection; still prevalent in low‑resource settings.
• Infective endocarditis – bacterial colonisation damages leaflets, leading to acute regurgitation.
• Ischemic heart disease – infarct‑related papillary‑muscle dysfunction causing mitral regurgitation.
• Hypertension – long‑standing high pressure induces left‑ventricular hypertrophy and secondary mitral regurgitation.

Risk factors

• Age > 60 years (degenerative disease)
• Male sex (higher prevalence of aortic stenosis)
• Family history of bicuspid aortic valve or early calcific disease
• History of rheumatic fever or untreated streptococcal infections
• Chronic kidney disease or dialysis (accelerated calcium deposition)
• Smoking, hyperlipidemia, and uncontrolled hypertension (promote vascular and valvular calcification)
• Previous chest radiation or cardiac surgery
• Connective‑tissue disorders (Marfan, Ehlers‑Danlos)

Diagnosis

Because early valve disease can be silent, most diagnoses arise from routine physical exams (murmur detection) or investigation of symptoms.

Clinical evaluation

• History and physical exam – auscultation for characteristic murmurs, assessment of pulse pressure, jugular venous pressure.
• Blood pressure, heart rate, and oxygen saturation.

Imaging and functional tests

• Echocardiography (transthoracic – TTE) – first‑line, provides valve anatomy, severity grading (pressure gradients, regurgitant volume), and ventricular function. 3‑D echo is increasingly used for surgical planning.
• Transesophageal echocardiography (TEE) – superior for detecting vegetation, prosthetic‑valve dysfunction, and detailed mitral pathology.
• Cardiac MRI – accurate quantification of regurgitant volume, assessment of myocardial fibrosis, and right‑ventricular involvement.
• Cardiac CT – excellent for evaluating aortic valve calcium score, annular sizing before transcatheter aortic valve replacement (TAVR).
• Stress testing (exercise or pharmacologic) – determines functional capacity and whether symptoms are exertional.
• Cardiac catheterization – reserved for concurrent coronary artery disease evaluation or when non‑invasive imaging is inconclusive.

Laboratory work‑up

• CBC, ESR/CRP if endocarditis suspected.
• Renal function (creatinine) – important for contrast imaging and medication dosing.
• BNP/NT‑proBNP – markers of heart‑failure decompensation.

Treatment Options

Treatment aims to relieve symptoms, halt disease progression, and prevent complications. The approach depends on valve type, severity, patient age, comorbidities, and surgical risk.

Medical management

• Heart‑failure drugs – ACE inhibitors, ARBs, beta‑blockers, and mineralocorticoid receptor antagonists improve ventricular remodeling.
• Diuretics – control pulmonary or systemic congestion.
• Anticoagulation – indicated for atrial fibrillation, prosthetic mechanical valves, or after certain endocarditis cases (warfarin or DOACs per guidelines).
• Anti‑platelet therapy – low‑dose aspirin for mild aortic stenosis or after TAVR.
• Antibiotic prophylaxis – recommended before dental procedures for patients with prosthetic valves or prior infective endocarditis (American Heart Association).

Surgical and percutaneous interventions

• Valve repair – preferred when feasible (e.g., mitral valve prolapse repair) because it preserves native tissue and has lower long‑term anticoagulation needs.
• Valve replacement – mechanical prosthesis (lifelong anticoagulation) or bioprosthetic tissue valve (limited durability). Choice guided by age, bleeding risk, and patient preference.
• Transcatheter Aortic Valve Replacement (TAVR) – minimally invasive option for severe aortic stenosis in patients ≥ 65 years or high‑risk younger patients. FDA‑approved for low‑risk patients as of 2022.
• Transcatheter Mitral Valve Repair (e.g., MitraClip) – indicated for symptomatic severe MR in patients deemed too high risk for surgery.
• Balloon valvuloplasty – temporary relief for severe mitral or pulmonic stenosis, mostly in rheumatic disease or congenital lesions.

Lifestyle and supportive measures

• Regular, moderate‑intensity aerobic exercise (e.g., brisk walking 30 min most days) as tolerated.
• Low‑sodium diet (<2 g/day) to reduce fluid overload.
• Weight management – maintain BMI 18.5–24.9 kg/m².
• Smoking cessation and limiting alcohol intake.
• Vaccinations (influenza, COVID‑19, pneumococcal) to lower infection‑related cardiac stress.

Living with Valve Disease (Heart Valve Disease)

Daily management tips

• Medication adherence – use a weekly pill organizer; set alarms.
• Symptom diary – record exertional dyspnea, swelling, or palpitations; share with your clinician.
• Activity pacing – break up chores; avoid sudden, strenuous exertion if you have severe stenosis.
• Fluid monitoring – if instructed, limit daily fluid intake (often 1.5–2 L) to avoid volume overload.
• Regular follow‑up imaging – echocardiograms every 1–2 years for mild disease; more frequent (6–12 months) when moderate‑severe.
• Dental hygiene – brush twice daily, use antiseptic mouthwash; keep dental appointments for prophylactic antibiotics when indicated.
• Travel considerations – carry a copy of your cardiac records, medications, and a letter from your cardiologist; stay hydrated and avoid high‑altitude extremes if severe pulmonary hypertension coexists.

Emotional & psychosocial support

Living with a chronic cardiac condition can be stressful. Consider joining patient‑support groups (e.g., American Heart Association “Heart Valve Disease Community”), and discuss mental‑health concerns with your healthcare team. Stress‑reduction techniques such as mindfulness, yoga, or gentle tai chi have been shown to improve quality of life in heart‑failure patients (Cleveland Clinic, 2022).

Prevention

• Control cardiovascular risk factors – blood pressure <120/80 mmHg, LDL < 70 mg/dL for high‑risk patients (AHA/ACC 2023).
• Prompt treatment of streptococcal throat infections – 10 day course of penicillin to prevent rheumatic fever.
• Healthy lifestyle – diet rich in fruits, vegetables, whole grains, and omega‑3 fatty acids; limit saturated fats and processed foods.
• Regular medical screening – especially for individuals with a family history of early valve disease or congenital lesions.
• Avoid illicit drug use – especially injectable drugs that raise endocarditis risk.
• Vaccination – influenza and COVID‑19 vaccines reduce systemic inflammation that can exacerbate valve disease.

Complications

If left untreated, valve disease can progress to life‑threatening conditions:

• Heart failure – both left‑ and right‑sided, leading to pulmonary edema, exercise intolerance, and systemic congestion.
• Arrhythmias – atrial fibrillation (common with mitral stenosis/regurgitation) and ventricular tachyarrhythmias in severe LV hypertrophy.
• Endocarditis – damaged or prosthetic valves are nidus for bacterial colonisation; mortality > 20 % without prompt treatment.
• Stroke – embolic events from atrial fibrillation or valve vegetations.
• Sudden cardiac death – particularly in severe aortic stenosis with syncope or in those with severe LV outflow obstruction.
• Pulmonary hypertension – secondary to chronic left‑sided pressure overload.
• Renal insufficiency – due to low cardiac output and chronic neurohormonal activation.

When to Seek Emergency Care

References

1. Mayo Clinic. “Heart valve disease.” Updated 2023. https://www.mayoclinic.org/…
2. American Heart Association. “Valvular Heart Disease.” 2022 Guideline Summary. https://www.heart.org/…
3. National Heart, Lung, and Blood Institute (NHLBI). “Valvular Heart Disease.” 2023. https://www.nhlbi.nih.gov/…
4. World Health Organization. “Rheumatic heart disease.” 2021 fact sheet. https://www.who.int/…
5. Cleveland Clinic. “Living with Heart Valve Disease.” Patient Education. 2022. https://my.clevelandclinic.org/…
6. U.S. Centers for Disease Control and Prevention. “Heart Disease Statistics.” 2023. https://www.cdc.gov/…
7. Society of Thoracic Surgeons and AHA/ACC Guidelines for the Management of Valvular Heart Disease, 2022.

```